August 15
To download program at a glance of UAA Congress 2025 :
15th August 2025
| Time | Session | |||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
08:30
17:00
|
TWTC - 1F Exhibition Hall
|
|||||||||||||||||||||||||||||
|
08:30
10:00
|
TICC - 3F Plenary Hall
|
TICC - 3F Banquet Hall
|
||||||||||||||||||||||||||||
|
10:00
10:30
|
TWTC - 1F Exhibition Hall
|
|||||||||||||||||||||||||||||
|
10:30
12:00
|
TICC - 3F Plenary Hall
|
TICC - 3F Banquet Hall
|
TICC - 1F 101D
|
Exploring Urology Service Challenges in ASEAN
TICC - 3F South Lounge
|
||||||||||||||||||||||||||
|
12:00
13:00
|
Mastering Suction Ureteroscopy: How the Right Laser and Scope Combination Makes the Difference
TICC - 3F Banquet Hall
|
Integrating Radioligand Therapy into mCRPC Clinical Practice: From Taiwan and Japan Experience
TICC - 2F 201BC
|
Time to Shift: From Medication Reliance to Minimally Invasive BPH Solutions
TICC - 2F 201AF
|
Collaborative Care: Mastering Techniques and Cardiovascular Considerations
TICC - 1F 101A
|
||||||||||||||||||||||||||
|
12:00
13:00
|
Optimising OAB Management to Advance Patient Outcomes
TICC - 1F 101D
|
Advances and Clinical Applications in ESWL Symposium
TICC - 3F South Lounge
|
Solution for Complicated Renal Stone: from RIRS to Ultramini ECIRS
TWTC - 1F Exhibition Hall
|
|||||||||||||||||||||||||||
|
13:30
15:00
|
TICC - 3F Plenary Hall
|
Effective Communication Conflict Resolution; Develop a Compelling Vision to Motivate Others
TICC - 3F Banquet Hall
|
||||||||||||||||||||||||||||
|
13:30
15:00
|
Infectious Disease / Urologic Trauma
TICC - 1F 101A
|
Advancing Focal Therapy in Localized Prostate Cancer: From Patient Stratification to Post-HIFU Management
TICC - 1F 101B
|
Redefining the journey of Genitourinary Cancer patients with Nivolumab
TICC - 1F 101C
|
TICC - 1F 101D
|
Transplantation
Cheng-Kuang YangTaiwan
Moderator
Robotic Radical Prostatectomy: Trying to Fit the Right Surgery to the Right PatientDefinitive treatment for localized prostate cancer included radical prostatectomy and radiation. Successful criteria of radical prostatectomy have to meet oncology control, not persistent PSA after surgery without salvage therapy. MRI imaging stage and PSA density are predictors for short‐term BCR after prostatectomy. NCCN‐defined high‐risk patients with a high initial PSA 28 density, imaging stage (T3aN0M0 and T3bN0M0), and 29 pathologic stage (any N1) had a higher risk of BCR when 30 compared with other patients with undetectable PSA, while 31 those with pathologic stage (T3bN0M0 or any N1) displayed 32 a higher risk of postoperatively detectable PSA. These find‐ 33 ings may help urologists to identify patients for whom active 34 therapeutic protocols are necessary.
TICC - 1F 102
|
|||||||||||||||||||||||||
|
13:30
15:00
|
Oncology Prostate
TICC - 3F South Lounge
|
Functional Urology
TICC - 3F North Lounge
|
Training and Education & AI in Urology
Chi-Fai NgHong Kong, China
Moderator
Novel Robotic Surgery PlatformsOver the past decades, robotic surgery has become an essential approach in urological care. The recent blooming of different robotic platforms, in particular in Asian countries, has helped popularize robotic surgery in less developed countries. The introduction of robotic technology in endoluminal surgery has also helped to open up opportunities to further improve endourology. In the future, the incorporation of AI in robotic systems will help upgrade the standard of care in urology.
William J. HuangTaiwan
Moderator
Male Infertility: Challenges and Opportunities in AsiaMale infertility contributes to nearly 50% of all infertility cases, with an increasing burden observed across Asia. In parallel, a dramatic decline in birth rates has emerged in several Asian countries—including South Korea, Japan, Taiwan, and Singapore—reaching historically low total fertility rates (TFRs) of under 1.0. While multifactorial in nature, this demographic crisis underscores the urgent need to address all aspects of reproductive health, including the often-overlooked role of male infertility. Epidemiological data reveal significant regional disparities in the prevalence, diagnosis, and treatment of male infertility. Cultural stigma, limited andrology training, fragmented referral systems, and inadequate coverage of assisted reproductive technologies (ART) have impeded timely diagnosis and intervention. Environmental exposures, endocrine-disrupting chemicals, occupational heat, and increased paternal age have all been linked to declining semen quality, as evidenced by longitudinal studies showing decreased sperm concentration and motility in several urban centers across Asia. Current diagnostic tools—including semen analysis, hormone profiling, genetic testing (e.g., Y-chromosome microdeletion, karyotyping), and imaging—enable better etiological categorization. Microsurgical sperm retrieval techniques such as mTESE have provided new hope for patients with non-obstructive azoospermia, while ICSI and sperm cryopreservation have become increasingly utilized where available. Nevertheless, access remains inconsistent, particularly outside metropolitan regions. Recent integration of AI-based systems for semen evaluation, patient triage, and digital counseling offers promising strategies to improve care delivery, especially in under-resourced settings. However, data privacy, regulatory standards, and user trust continue to pose barriers to widespread implementation. Opportunities for systemic improvement include the development of regional male infertility registries, integration of andrology into national reproductive health frameworks, expansion of insurance coverage for fertility services, and public awareness campaigns to destigmatize male infertility. In light of Asia’s fertility decline, repositioning male reproductive health as a public health and demographic priority is essential for sustainable population policy and long-term healthcare planning.
The Peri-Operative Care of MIST For Prostate HyperplasiaMinimally invasive surgical therapies (MIST), particularly UroLift and Rezūm, have transformed the treatment landscape for benign prostatic hyperplasia (BPH), offering effective symptom relief with reduced morbidity and preservation of sexual function. However, optimal outcomes depend not only on procedural execution, but also on well-structured peri-operative care protocols encompassing pre-, intra-, and post-operative management. Pre-operative evaluation includes comprehensive assessment of prostate anatomy—especially size, shape, and presence of median lobe—via imaging (TRUS or cystoscopy) to determine candidacy. Careful patient selection is essential: UroLift is typically suited for prostates <80 cc without obstructive median lobes, while Rezūm accommodates broader anatomical variability but may have delayed symptom resolution. Baseline symptom scores (e.g., IPSS), uroflowmetry, and post-void residual volume establish functional benchmarks and guide patient counseling. Anesthesia planning must consider procedural setting and patient comorbidities. UroLift can often be performed under local anesthesia with light sedation, whereas Rezūm may require short general anesthesia or deeper sedation due to thermal discomfort. Appropriate selection reduces intraoperative stress and facilitates same-day discharge. Intraoperative care focuses on minimizing trauma and ensuring device precision. UroLift requires accurate deployment of implants to maintain lateral lobe retraction without compromising sphincter integrity. In Rezūm, the number and duration of vapor injections must be titrated based on lobe size and configuration to balance efficacy and tissue inflammation. Real-time visualization and standardized protocols reduce variability and improve safety. Post-operative management involves anticipating and controlling transient irritative symptoms, such as dysuria, urgency, and hematuria. Alpha-blockers and anti-inflammatory medications are commonly used for 3–7 days post-procedure. Catheterization strategies differ by technique: UroLift may avoid catheter use entirely, whereas Rezūm often requires 7-14 days of catheter drainage due to anticipated edema. Monitoring for urinary retention, UTI, or clot obstruction is critical during the early recovery phase. Follow-up care typically occurs at 2–4 weeks and includes reassessment of voiding function, symptom scores, and patient satisfaction. Reinforcement of realistic expectations is especially important with Rezūm, which may take 4–6 weeks to achieve peak efficacy. Longitudinal studies indicate sustained symptom relief and low retreatment rates when peri-operative care is standardized and patient education is emphasized. Adverse event profiles differ between techniques: UroLift is associated with less dysuria but higher retreatment rates in large prostates, while Rezūm presents higher rates of transient discomfort but favorable durability. Structured peri-operative care pathways—including patient education, standardized medication protocols, and clear complication management plans—enhance recovery, minimize adverse events, and improve overall clinical success.
TICC - 4F Elegance Lounge
|
Oncology Prostate (B)
TICC - 4F Joy Lounge
|
Novel Advances (A): Prostate
TWTC - 1F Exhibition Hall
|
|||||||||||||||||||||||||
|
13:30
17:00
|
Flexible Ureterorenoscopy: Technique, Tips, Tricks and Indications
TWTC - 2F Conference Room A+
|
|||||||||||||||||||||||||||||
|
15:00
15:30
|
TWTC - 1F Exhibition Hall
|
|||||||||||||||||||||||||||||
|
15:30
17:00
|
TICC - 3F Plenary Hall
|
|||||||||||||||||||||||||||||
|
15:30
17:00
|
Oncology Bladder UTUC (B)
TICC - 1F 101A
|
Current Trends in Management of Advanced Urothelial Carcinoma
TICC - 1F 101B
|
Innovations in Urolithiasis Treatment: Clinical Evidence on mediNiK and Insights of Hydrogel-Suction Synergy
TICC - 1F 101C
|
Oncology RCC (A)
Cheryn SongKorea (Republic of)
Moderator
Assistance of the AI during RAPN - Surgical Navigation to Outcome PredictionArtificial Intelligence (AI) has deeply infiltrated many, if not every, aspects of our lives - both professional and ordinary corners. In medicine, it seems that any research dealing with large amounts of data has to employ AI in one way or another - from radiomics and radiogenomics to drug developments and simulations. In managing patients with renal tumors, majority of which now present with localized, small masses, I have focused on developing a tool to help establish a plan preoperatively and navigate throughout the surgery, in real-time with the help of the AI. Using kidney dynamic CT scans of 100 patients undergoing robot-assisted partial nephrectomy, software was developed to render a 3-dimensional image of the kidney harboring the tumor along with several other tools to enhance visualization of the lesion. Scans from an additional 30 patients were used to test for performance and validate the software. Before surgery, main renal pedicles, tumor location with respect to the major hilar vasculature, important landmarks including the calyces and branches of the vessels can be studied from all angles; tumor shape especially when it is not a perfect sphere can be visually presented and the excision of the tumor with desired margin thickness can be simulated to see what vital structures come into contact. Connected to the surgeon console through the TilePro® screen, it was designed to aid a urologic surgeon from before surgery as well as throughout the procedure as needed. In a phase I feasibility trial investigating the efficacy of the system, we confirmed that the integration of the 3D navigation system into RAPN was both feasible and safe, providing enhanced anatomical information while maintaining a consistent level of operative risk. The use of navigation system resulted in reduced renal parenchymal volume resected, suggesting potential benefits in renal function preservation. Subsequent phase 2 trial investigating accuracy of the reconstruction and a multicenter randomized controlled trial with surgeons with varying degrees of experience are underway to validate the benefits.
On the other hand, the fundamental question as to best manage the small renal masses – i.e. indications for partial nephrectomies - still harbor some gray areas: is partial nephrectomy at all possible situations the best? In a given patient how will oncological and renal functional outcome differ between partial and radical nephrectomy? Previous statistical methods could only calculate risk ratios in the best-matched cohorts and the issue of counterfactual remained. Using demographic and tumor descriptive parameters of 1,448 patients with pT1N0M0 RCC patients from three academic centers, causal inference was modeled using a double machine learning algorithm to predict progression-free survival and eGFR at five years according to each surgical method: partial and radical nephrectomy. We identified significant factors and their contribution to the outcomes of interest to be included in the model. Selecting a model with the highest performance among various machine learning models for each outcome, an online interface was constructed. External validation confirmed the robustness, presenting AUROC of 0.758, AUPRC of 0.200 with XGBoost model for recurrence, and RMSE of 15.9 with GBM model for eGFR. By presenting numerical predictions of oncologic and functional outcomes associated with partial and radical nephrectomy in a given patient, our model facilitates individualized, evidence-based clinical decision-making.
TICC - 1F 101D
|
Pediatric Urology
Shang-Jen ChangTaiwan
Moderator
Which Surgical Treatment is Best for UPJO in Infants: Open, Laparoscopic, Robotic AssistedAbstract
Ureteropelvic junction obstruction (UPJO) in infants is a condition that can significantly impair renal function and requires timely surgical intervention when certain criteria are met, such as decreased split renal function, poor drainage on diuretic renography, or recurrent urinary tract infections. The three main surgical approaches for treating UPJO are open pyeloplasty (OP), laparoscopic pyeloplasty (LP), and robot-assisted laparoscopic pyeloplasty (RALP). Each technique has its own benefits and limitations, especially when applied to infants.
Minimally invasive surgery (MIS), including LP and RALP, has gained popularity in pediatric urology due to advantages such as shorter hospital stays, reduced postoperative pain, faster recovery, and better cosmetic outcomes. However, the small working space in infants, the steep learning curve, and higher costs are significant limitations. In particular, the utility of MIS in infants remains controversial due to undefined benefits and technical challenges, including limited space for trocar placement and difficulty in intracorporeal suturing.
Current guidelines from the European Association of Urology (EAU) indicate that while RALP is considered the gold standard for older pediatric patients, its role in infants remains less defined due to anatomical and logistical constraints. Open surgery continues to be the mainstay for infantile UPJO due to its well-established success rate and lower cost.
Several studies have addressed the learning curve associated with these techniques. Laparoscopic pyeloplasty requires about 30 cases for a surgeon to achieve proficiency, while RALP demands approximately 18–31 cases depending on the metrics used. Simulation-based training, dry labs, and multicenter collaboration are proposed solutions to accelerate skill acquisition and ensure patient safety.
Cost is another critical consideration. Although RALP generally incurs higher upfront costs, especially in low-volume centers, innovations such as magnetic stents have helped offset some of these expenses by eliminating the need for anesthesia during stent removal. Moreover, the availability of pediatric-specific robotic instruments remains limited and necessitates ongoing development to fully support MIS in smaller patients.
In conclusion, while RALP is increasingly recognized as the standard for pediatric UPJO, its application in infants should be considered selectively, depending on surgeon experience, institutional resources, and patient anatomy. Open pyeloplasty remains a safe and effective option, particularly in very young children. Advances in surgical training, cost reduction strategies, and instrument development will be key to expanding the use of minimally invasive techniques in this population.
TICC - 1F 102
|
|||||||||||||||||||||||||
|
15:30
17:00
|
Oncology: RCC & Miscellaneous
TICC - 3F South Lounge
|
Pediatric Urology & Infectious Disease
Yu-Chen ChenTaiwan
Moderator
What We Should Know about Sexual Development Disorders Disorders of Sexual Development (DSDs) represent a spectrum of congenital conditions involving atypical development of chromosomal, gonadal, or anatomical sex. Early identification and accurate diagnosis are essential for guiding clinical management and psychosocial support. This talk will provide an overview of the classification of DSDs, including 46,XX DSD, 46,XY DSD, and sex chromosome DSDs, and highlight key diagnostic steps such as hormonal profiling, genetic testing, and imaging studies. Common conditions such as congenital adrenal hyperplasia (CAH), androgen insensitivity syndrome (AIS), and gonadal dysgenesis will be discussed, with emphasis on a multidisciplinary approach involving pediatric endocrinologists, geneticists, surgeons, and psychologists. Practical considerations in gender assignment, surgical timing, and long-term follow-up will also be addressed. This session aims to equip urology residents with the essential knowledge to recognize and contribute to the care of patients with DSDs.
TICC - 3F North Lounge
|
Oncology Prostate (C)
Chang Wook JeongKorea (Republic of)
Moderator
Extravasculare Renal Denervation to Treat Resistant HypertensionResistant hypertension is defined as uncontrolled blood pressure above the target, despite the concurrent use of three or more antihypertensive medications. Individuals with resistant hypertension are at a high risk for severe cardiovascular events and mortality. Managing resistant hypertension is challenging, and many non-pharmacological treatments, including renal denervation (RDN), have been introduced.
This presentation will demonstrate the surgical technique of the extravascular RDN (eRDN) using the HyperQure™ System performed as part of the first-in-human trial. The surgeries were performed as a retroperitoneal approach in a modified prone position.
The preliminary results will be presented, too. In the United States, a prospective, multicenter, early feasibility study is also underway.
TICC - 4F Elegance Lounge
|
Bladder UTUC (C)
TICC - 4F Joy Lounge
|
Novel Advances (B): Bladder
Jian-Ri LiTaiwan
Moderator
Applying Vision Augmentation in Robotic Surgery: Reality or FictionApplying Vision Augmentation in Robotic Surgery: Reality or Fiction
Seong Il SeoKorea (Republic of)
Moderator
Comparison of Remal Function between Radiofrequency Ablation versus Robot Assisted Laparoscopic Patial Nephrectomy for Small Renal Mass in Elderly PatientsComparison of renal function between radiofrequency ablation versus robot assisted laparoscopic partial nephrectomy for small renal mass in elderly patients
Jiwoong Yu, Seongil Seo
Sungkyunkwan University, Samsung Medical Center
The incidence of small renal masses (SRMs) in patients ≥75 years has increased up to 30-fold [J Urol 2014]. In this age group, treatment should balance cancer control and renal function preservation. Robot-assisted partial nephrectomy (RAPN) and radiofrequency ablation (RFA) are two main options.
RAPN offers excellent cancer control but requires general anesthesia and ischemia, which may pose risks in older patients. RFA is less invasive, avoids vascular clamping, and is often preferred for high-risk patients, as supported by EAU and AUA guidelines.
RFA generally preserves renal function better [Front Oncol 2022], though outcomes vary by technique. At our center, RFA under general anesthesia with wide safety margins may compromise parenchymal preservation.
While both approaches show favorable cancer control, RFA has a slightly higher recurrence rate. Pantelidou et al. reported 6 recurrences in 63 RFA cases vs. 1 in 63 RAPN cases [Cardiovasc Intervent Radiol 2016], and Park et al. reported 2-year recurrence-free survival (RFS) of 95.2% in RFA vs. 100% in RAPN [Eur Radiol 2018]. NCCN guidelines note that RFA may require repeat treatment to match surgical outcomes.
Our institutional matched analysis (63 RAPN vs. 63 RFA) showed RFS of 100% vs. 95.2% (p = 0.029), and immediate eGFR preservation of 91.7% vs. 86.8% [Eur Radiol 2018;28:2979–2985]. A subsequent analysis of older patients presented at AUA 2024 included 137 patients aged ≥75, the rate of ≥25% eGFR decline at one year was 28.6% for RFA vs. 2.0% for RAPN (HR 11.3, p = 0.002), with 4 recurrences in RFA and none in RAPN.
In conclusion, both RFA and RAPN are viable options for elderly patients with small renal masses. RFA is less invasive but may carry a slightly higher risk of recurrence and, depending on institutional technique, some degree of renal function loss. Treatment should be individualized based on tumor anatomy, patient condition, and institutional expertise.
TWTC - 1F Exhibition Hall
|
|||||||||||||||||||||||||